AbbVie Inc. (ABBV) Stock Price & How to Invest

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

AbbVie was led by founder Richard Gonzalez from its 2013 spin-off until late 2023, when Robert A. Michael became chief executive officer. Under Gonzalez, AbbVie transformed from a Humira-dependent entity into a diversified biopharma by acquiring Pharmacyclics (2015), Stemcentrx (2016), and Allergan (2020) for a combined investment exceeding $80 billion. Michael took the helm as the Humira loss-of-exclusivity cycle was cresting and has since overseen record net revenues of $61.16 billion in full-year 2025, a figure that the company says surpassed the previous Humira-era revenue peak in only the second year following U.S. Humira biosimilar entry. AbbVie employs roughly 57,000 people globally and trades on the New York Stock Exchange.

The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AbbVie Inc.'s investor relations page or your broker.

• Revenue (FY 2025, reported): ~$61.2 billion
• Adjusted Diluted EPS (FY 2025): $10.00
• GAAP Diluted EPS (FY 2025): $2.36
• Forward P/E (consensus FY 2026 estimate): ~15.7x
• EV/EBITDA (TTM): ~15.9x
• Dividend Yield (TTM, as of late June 2026): ~3.0%
• Free Cash Flow (FY 2025): ~$17.8 billion
• Market Capitalization (approx.): ~$403 billion

The large gap between the trailing GAAP P/E (elevated, reflecting non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 15.7x illustrates why analysts and management prefer adjusted metrics: large upfront licensing and milestone payments depress reported earnings without reducing cash generation. On a free cash flow basis, AbbVie trades at a more modest multiple, and the PEG ratio near 0.91 suggests the consensus earnings growth rate is tracking faster than the headline valuation implies. The 2026 revenue guidance of roughly $67 billion and adjusted EPS of $14.37 to $14.57 would, if achieved, represent meaningful upward re-rating from 2025 reported figures.

If you want ABBV exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

There are three common ways to get ABBV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (HDV, NOBL, DGRO), which spreads the position across many companies. Or build it into a focused thematic basket, so ABBV sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ABBV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AbbVie is, right now, a post-Humira compounder in the process of re-rating: its immunology successor franchise (Skyrizi plus Rinvoq at roughly $25.9 billion in 2025 combined revenue, already past the company's old 2027 peak target) is demonstrating that the business can grow faster than most large-cap pharma peers, and the company is guiding to roughly $67 billion in 2026 revenue and $14.37 to $14.57 in adjusted EPS. If you believe the Skyrizi and Rinvoq growth curve sustains through the late 2020s, that the neuroscience and oncology portfolios add a meaningful second layer, and that management can deploy its roughly $17 to $18 billion in annual free cash flow into value-accretive pipeline deals, the question becomes sizing and overlap with other healthcare positions, not timing; the risk is that a few products carry most of the weight, and a clinical, regulatory, or pricing shock to any of them would remove a disproportionate share of the thesis.

Whether ABBV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ABBV a buy?, and where the stock could go from here in the ABBV stock forecast.

For income investors, whether ABBV pays a dividend and how the payout looks is covered in does ABBV pay a dividend?